Edaravone (MCI-186) is effective as a free radical scavenger following arteriovenous sheathotomy for treatment of macular oedema associated with branch retinal vein occlusion
- 1Tane Memorial Eye Hospital, Osaka, Japan
- 2Department of Ophthalmology, Osaka Medical College, Takatsuki, Japan
- Correspondence to Dr T Maeno, Tane Memorial Eye Hospital, 1-1-39 Sakaigawa Nishi-ku, Osaka, Osaka 550-0024, Japan; tanemem{at}io.ocn.ne.jp
- Accepted 2 May 2009
- Published Online First 9 August 2009
Abstract
Aims: To determine whether edaravone (MCI-186), a free radical scavenger, can reduce macular oedema and improve the visual acuity after arteriovenous sheathotomy in eyes with a branch retinal vein occlusion (BRVO).
Methods: Forty-seven eyes of 47 consecutive patients with a BRVO who were treated with arteriovenous sheathotomy were studied. The patients were assigned prospectively to either Group R who received 30 mg of edaravone (Radicut) systemically during the vitrectomy or Group N who did not receive any drugs. The postoperative visual acuity was measured before and 12 months after the operation.
Results: At 12 months postoperatively, the best-corrected visual acuity (BCVA) in logarithm of the minimum angle of resolution (logMAR) units improved significantly from 0.22 to 0.56 logMAR units in Group R and from 0.20 to 0.27 units in Group N (p = 0.016). Twenty-three of 27 cases (85%) in Group R and four of 15 cases (27%) in Group N showed an improvement in BCVA of >0.2 logMAR units (p = 0.0025).
Conclusion: The better visual acuity in patients given edaravone than those without endaravone during the arteriovenous sheathotomy suggests that edaravone improved the physiology of the retinal cells after the arteriovenous sheathotomy.
Footnotes
-
Competing interests None declared.
-
Provenance and Peer review Not commissioned; externally peer reviewed.
-
Ethics approval Obtained from the Ethics Committee of Tane Hospital.
-
Patient consent Obtained







